BioSpace News Archive

The process began in 2019 when the Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, launched SMASH Packaging.

SG Austria (“Austrianova”), a leading provider of cell biological products and services, today announced that it has established a German subsidiary company based in Munich and moved to a new location in Singapore.

Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November 9, 2023 to discuss Medexus’s results for its second fiscal quarter ended September 30, 2023.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it has exceeded 50% of the patient enrollment target for its Phase II open-label pilot study

Mirion, a leading provider of advanced radiation safety solutions, announced a philanthropic partnership with RAD-AID International to help bring radiology and radiation safety education and capabilities to underserved populations around the world.

Siren Biotechnology announced that the California Institute for Regenerative Medicine has awarded the company a $4M translational research grant to support the development of novel AAV immuno-gene therapies for cancer.

Regeneron Pharmaceuticals, Inc. announced long-term outcomes and new analyses of pivotal clinical data for EYLEA® HD Injection 8 mg will be presented at the American Academy of Ophthalmology annual meeting in San Francisco from November 3 to 6.

LeMaitre, a provider of vascular devices, implants and services, reported Q3 2023 results, announced a $0.14/share quarterly dividend and provided guidance.

BioMarin Pharmaceutical Inc. announced that Alexander Hardy has been named president and chief executive officer, succeeding Jean-Jacques Bienaimé, who will retire as chairman and CEO effective December 1, 2023.

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that the company generated revenue of $628.3 million for the third quarter ended September 30, 2023, compared to $523.1 million for the same period of 2022.